Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Total Current Liabilities (2016 - 2025)

Mimedx (MDXG) has disclosed Total Current Liabilities for 15 consecutive years, with $64.3 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 40.95% to $64.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.3 million through Dec 2025, up 40.95% year-over-year, with the annual reading at $64.3 million for FY2025, 40.95% up from the prior year.
  • Total Current Liabilities hit $64.3 million in Q4 2025 for Mimedx, up from $57.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $64.3 million in Q4 2025 to a low of $36.6 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $45.6 million across 5 years, with a median of $43.6 million in 2022.
  • Biggest five-year swings in Total Current Liabilities: crashed 33.96% in 2022 and later skyrocketed 40.95% in 2025.
  • Year by year, Total Current Liabilities stood at $42.4 million in 2021, then grew by 2.83% to $43.6 million in 2022, then rose by 5.63% to $46.0 million in 2023, then dropped by 0.9% to $45.6 million in 2024, then surged by 40.95% to $64.3 million in 2025.
  • Business Quant data shows Total Current Liabilities for MDXG at $64.3 million in Q4 2025, $57.7 million in Q3 2025, and $50.3 million in Q2 2025.